Company Performance Metrics
- Past Role: Ohm Oncology, Chief Operating Officer
- Past Role: Ohm Oncology, Chief Operating Officer
Fe Pharmaceuticals is reversing the effects of disrupted iron management in disease. Dysregulation of iron homeostasis can lead to or exacerbate a wide variety of diseases including infection, cancer, and inflammatory diseases. Fe Pharmaceuticals is developing DIBI, a non-toxic, iron-binding copolymer, as a potent, broad-spectrum, antimicrobial
agent active against bacterial and fungal infections, including drug resistant organisms. DIBI starves infections for essential iron. DIBI is also effective against sepsis, inflammatory disorders, and cancer. This water-soluble polymer is ideal for many routes of administration and has been characterized in 22 published studies. It is non-toxic in animal studies and is immune to the development of microbial resistance and inhibits the development of resistance to co-administered antibiotics with which it is synergistic. NIAID is supporting development and MBC Biolabs has accepted our US subsidiary into its Bay area incubator. The company is raising a Series A to advance DIBI through Phase 1.
